Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
August 03 2021 - 4:07PM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced the closing of its upsized initial public
offering of 8,625,000 shares of Class A common stock, including the
full exercise by the underwriters of their overallotment option to
purchase 1,125,000 shares of Class A common stock, at a public
offering price of $15.00 per share, for total gross proceeds of
approximately $129.4 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Immuneering.
Immuneering’s Class A common stock began trading on the Nasdaq
Global Market under the ticker symbol “IMRX” on July 30, 2021.
Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted
as joint book-running managers.
A registration statement relating to the securities being sold
in the offering was declared effective by the U.S. Securities and
Exchange Commission on July 29, 2021. This offering is being made
only by means of a prospectus. Copies of the final prospectus
relating to this offering may be obtained, when available, by
contacting: Morgan Stanley & Co. LLC, Attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by
email at prospectus@morganstanley.com; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, by telephone at (877) 821-7388 or by
e-mail at prospectus_department@jefferies.com; or Cowen and
Company, LLC, c/o Broadridge Financial Services, 1155 Long Island
Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by
telephone at 833-297-2926.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of such
state or jurisdiction.
About Immuneering
Corporation
Immuneering is a biopharmaceutical company with
an emerging pipeline focused on improving patient outcomes across a
spectrum of debilitating oncologic and neurologic diseases by
applying its deep knowledge of translational bioinformatics to
every stage of the drug development process. Immuneering has more
than a decade of experience in translational bioinformatics and
generating insights into drug mechanisms of action and patient
treatment responses. Building on this experience, Immuneering has
developed a disease-agnostic platform that enables the company to
utilize human data, novel biology and chemistry, and translational
planning to create and advance its wholly owned pipeline.
Immuneering’s current development programs in oncology are focused
on providing potential treatments for patients with solid tumors
caused by mutations of oncologic signaling pathways, including the
MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is
designed to be a highly selective dual-MEK inhibitor that further
disrupts KSR for the treatment of advanced solid tumors in patients
harboring RAS mutant tumors. Additionally, Immuneering has six
other oncology programs in the discovery stage that are designed to
target either the MAPK or mTOR pathway, and two neuroscience
programs in the discovery
stage.
Forward-Looking Statements
This press release includes certain disclosures
that contain "forward-looking statements," including, without
limitation, statements regarding Immuneering’s anticipated use of
net proceeds from the offering. Forward-looking statements are
based on Immuneering’s current expectations and are subject to
inherent uncertainties, risks and assumptions that are difficult to
predict. Factors that could cause actual results to differ include,
but are not limited to, the risks inherent in oncology and
neuroscience drug development, including target discovery, target
validation, lead compound identification, lead compound
optimization, preclinical studies and clinical trials. These and
other risks and uncertainties are described more fully in the
section titled "Risk Factors" in the final prospectus related to
the offering filed with the U.S. Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Immuneering undertakes
no duty to update such information except as required under
applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Anne Marie FieldsManaging
DirectorRx Communications afields@rxir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024